SCIENCE LIBRARY · UNITED STATES
Original scientific explainers with study data, limitations and links to practical guides. Each study is interpreted in its own population and treatment context.
Start with the outcome you want to understand. A change in weight, a symptom score and a reduction in clinical events answer different questions.
Browse the chart and data collection →SCIENTIFIC ARTICLE
Semaglutide reduced major cardiovascular events in people with established cardiovascular disease, overweight or obesity, and no diabetes. Understanding the result means keeping the population, event counts, time horizon, and treatment discontinuations in view.
SCIENTIFIC ARTICLE
Semaglutide reduced a combined kidney and cardiovascular outcome in adults with type 2 diabetes and chronic kidney disease. Understanding the entry criteria, event counts, and kidney-function measurements makes the result more useful than a headline percentage.
SCIENTIFIC ARTICLE
The withdrawal trial strongly favored continued treatment, but its two baselines, selected population, and newer dose-reduction research matter when interpreting the result.
SCIENTIFIC ARTICLE
A year after semaglutide and structured lifestyle support ended, participants regained much—but not all—of their average weight loss. Understanding the selected sample, changing denominators, and unanswered questions matters more than treating that average as a personal forecast.
SCIENTIFIC ARTICLE
Tirzepatide produced greater average weight loss than semaglutide over 72 weeks in a randomized trial. Understanding the comparison requires looking beyond the headline percentages to the regimens, statistical estimates, safety evidence, and questions the trial did not test.
SCIENTIFIC ARTICLE
Two tirzepatide trials found substantial reductions in sleep-apnea events over 52 weeks. Understanding the results requires separating hourly measurements, PAP-use groups, average improvement, and the question of residual disease.
SCIENTIFIC ARTICLE
Semaglutide improved symptoms, walking performance, and weight in a 52-week trial. Understanding those results means separating health-status scores from hospital events, mortality, and evidence about other medicines.
SCIENTIFIC ARTICLE
Tirzepatide reduced a combined cardiovascular-death or worsening-heart-failure outcome in people with obesity and preserved ejection fraction. Understanding the result means separating the components, the symptom score, and the remaining uncertainty.
SCIENTIFIC ARTICLE
Tirzepatide substantially reduced progression to type 2 diabetes in participants with obesity and prediabetes. The important questions are what was measured, how long the difference lasted, and what remains unknown after treatment stopped.
SCIENTIFIC ARTICLE
The SURMOUNT-1 DXA substudy found substantially more fat loss than lean-mass loss. Understanding its denominators, small analysis population, and missing strength measurements is essential to interpreting that result.